Clinical Trial Update: Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on safety and dosing for BT062 in patients with relapsed or refractory multiple myeloma; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BT062

Snippet

Sponsor: Biotest Pharmaceuticals Corporation | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-08